Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

(2019) Satomi Watanabe et al.   Cancer Medicine

MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer

(2019) Ofra Novoplansky et al.   INTERNATIONAL JOURNAL OF CANCER

ErbB3 Ligand Heregulin1 Is a Major Mitogenic Factor for Uncontrolled Lung Cancer Cell Proliferation

(2019) Shiqi Ma et al.   NEOPLASIA

A Combination Of Approved Antibodies Overcomes Resistance Of Lung Cancer To Osimertinib By Blocking Bypass Pathways

(2018) Donatella Romaniello et al.   CLINICAL CANCER RESEARCH

Irreversible modifications of receptor tyrosine kinases

(2018) Matthew Kreitman et al.   FEBS LETTERS

Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

(2018) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiac Toxicity from Breast Cancer Treatment: Can We Avoid This?

(2018) Jesse Caron et al.   Current Oncology Reports

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

(2017) Luis J Schwarz et al.   JNCI-Journal of the National Cancer Institute

Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer

(2017) Kimio Yonesaka et al.   LUNG CANCER

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor

(2017) Toni M. Brand et al.   Science Signaling

Soluble HER3 predicts survival in bladder cancer patients

(2017) Ashfaque Memon et al.   Oncology Letters

Proteolytic cleavages in the extracellular domain of receptor tyrosine kinases by membrane-associated serine proteases

(2017) Li-Mei Chen et al.   Oncotarget

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

(2017) Luis J Schwarz et al.   JNCI-Journal of the National Cancer Institute

The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor

(2017) Toni M. Brand et al.   Science Signaling

Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors

(2016) Maicol Mancini et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance

(2016) M. A. Miller et al.   Cancer Discovery

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

(2016) Yue-Lun Zhang et al.   Oncotarget

Activated ErbB3 Translocates to the Nucleus via Clathrin-independent Endocytosis, Which Is Associated with Proliferating Cells

(2015) Raymond Reif et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

(2015) K Yonesaka et al.   ONCOGENE

Examination of HER3 targeting in cancer using monoclonal antibodies

(2015) Nadège Gaborit et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

(2015) Maicol Mancini et al.   Science Signaling

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

(2015) Maicol Mancini et al.   Science Signaling

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

(2014) C. M. Lovly et al.   CLINICAL CANCER RESEARCH

Oncogenic ERBB3 Mutations in Human Cancers

(2013) Bijay S. Jaiswal et al.   CANCER CELL

Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models

(2013) D. Siolas et al.   CANCER RESEARCH

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

(2012) K. Ohashi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

(2012) Ken Takezawa et al.   Cancer Discovery

HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer

(2011) Chantal Tsé et al.   CANCER TREATMENT REVIEWS

Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3

(2011) L. Chen et al.   CLINICAL CANCER RESEARCH

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Mechanistic insights into the activation of oncogenic forms of EGF receptor

(2011) Zhihong Wang et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors

(2011) A. C. Faber et al.   Cancer Discovery

The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer: A Meta-Analysis of Published Data

(2010) Lingxiang Liu et al.   Journal of Thoracic Oncology

Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells

(2009) M. Narayan et al.   CANCER RESEARCH

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

ADAMs 10 and 17 Represent Differentially Regulated Components of a General Shedding Machinery for Membrane Proteins Such as Transforming Growth Factor α, L-Selectin, and Tumor Necrosis Factor α

(2009) Sylvain M. Le Gall et al.   MOLECULAR BIOLOGY OF THE CELL

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations

(2008) S. Yano et al.   CANCER RESEARCH